---
schema_version: "secwatch.filing_event.v1"
accession: "0000950142-22-002532"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:53:30.749497+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics appoints Dr. Jonathan Isaacsohn as Chair of the Board

## Summary
- Dr. Jonathan Isaacsohn appointed as member and Chair of Board effective August 9, 2022.
- He is President and CEO of CinRx Pharma, LLC; appointment per July 22, 2022 stock purchase agreement.
- Annual cash compensation of $70,000 plus annual equity grant of 50,000 options; initial grant of 50,000 options on appointment.
- Dr. Isaacsohn has over 25 years in drug development; served as CMO of Teva Pharmaceutical Industries.

## SEC filing metadata
- accession: 0000950142-22-002532
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000095014222002532/0000950142-22-002532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000095014222002532/eh220279180_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950142-22-002532
- JSON: https://secwatch.observer/filing/0000950142-22-002532.json
- Plain text: https://secwatch.observer/filing/0000950142-22-002532.txt

## Key facts
- Executive change
  Dr. Jonathan Isaacsohn was appointed as Chair of the Board at vTv Therapeutics Inc..
  - Action: appointed
  - Role: Chair of the Board
  source text: appointed Dr. Jonathan Isaacsohn as a member and chair of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000095014222002532/0000950142-22-002532-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.